This group of diseases is characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
Along with the well known routine laboratory parameters, measurement of factor H and metalloproteinases namely ADAMTS13 is recommended.
The pathogenetic link is the occlusion of microvessels by microthrombi. The resulting insufficient perfusion is responsible for the organ specific symptoms.
1. |
Nürnberger J et al. (2009) Eculizumab for atypical hemolytic-uremic syndrome. |
2. |
McCrae KR et al. (2001) Platelets: an update on diagnosis and management of thrombocytopenic disorders. |
3. |
None (2002) Thrombotic microangiopathies. |
4. |
Shah NT et al. (2003) Controversies in differentiating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. |
5. |
Wikipedia article Wikipedia EN (Thrombotic_microangiopathy) |